Defendant shall be punished by a fine of KRW 5,000,000.

When the defendant does not pay the above fine, 100,000 won.

Punishment of the crime

The defendant is the actual operator of C corporation, the business purpose of which is human resources management service, such as parking management and expenses, in Seocho-gu Seoul Metropolitan Government.

1. A person who intends to engage in the business of manufacturing quasi-drugs shall install necessary facilities and file a manufacturing business report with the Minister of Food and Drug Safety, and obtain marketing approval or file marketing notification by item;

Nevertheless, from June 2013 to April 2014, the Defendant manufactured 71,00 "Dmast", which is a quasi-drugs that has indicated efficacy, such as "prevention of spawn infection" and "prevention of secondary infections of surgery patients and prevention of infectious diseases", without permission from the Minister of Food and Drug Safety, at the office of the above C Co., Ltd. from June 2013 to April 2014.

2. No one shall sell, store or display for sale, any quasi-pharmaceutical product manufactured or imported without obtaining marketing approval or filing marketing notification from the Minister of Food and Drug Safety;

Nevertheless, from June 18, 2013 to June 17, 2014, the Defendant sold 41,000, totaling 62,810,070 won at the market price, via E companies, pharmacies, etc., a quasi-pharmaceutical, which was not approved by the Minister of Food and Drug Safety.

Summary of Evidence

1. Defendant's legal statement;

1. Investigation report (Confirmation of a manufacturer without filing a report), investigation report (Dmake labeling), investigation report (related to a manufacturer with no filing a report), investigation report (related to a company EF&C), investigation report (related to a manufacturer with no filing a report), investigation report (finding report on non-pharmaceutical product verification), investigation report (Dmast's non-pharmaceutical product verification), investigation report (Dmast's printing), investigation report (verification of manufacturing activity of Dmast's finished product), investigation report (CC's manufacturing quantity), and sales of Dma finished product;

1. To purchase the current status of the report on items of non-pharmaceutical drugs, details of the purchase of marina content, details of the sales of DNA, details of the purchase of Masck in the sck condition, and packing paper;